Top

Published in:

01-08-2022 | Urolithiasis | Original Article

Puerarin prevents calcium oxalate crystal-induced renal epithelial cell autophagy by activating the SIRT1-mediated signaling pathway

Authors: Guan-Hua Jing, Ya-Dong Liu, Jian-Nan Liu, Yin-Shan Jin, Shi-Liang Yu, Rui-Hua An

Published in: Urolithiasis | Issue 5/2022

Abstract

Calcium oxalate (CaOx) crystals can activate autophagy, causing damage to renal tubular epithelial cells (TECs). Puerarin has been shown to have protective and therapeutic effects against a variety of diseases by inhibiting autophagy activation. However, the protective effect of puerarin against CaOx crystals and the underlying molecular mechanisms are unclear. Cell Counting Kit-8 (CCK-8) assays were used to evaluate the effects of puerarin on cell viability. Intracellular reactive oxygen species (ROS) levels were measured by the cell-permeable fluorogenic probe 2,7-dichlorofluorescein diacetate (DCFH-DA). Immunofluorescence, immunohistochemistry, and western blotting were used to examine the expression of SIRT1, Beclin1, p62, and LC3, and explore the underlying molecular mechanisms in vivo and in vitro. Puerarin treatment significantly attenuated CaOx crystal-induced autophagy of TECs and CaOx cytotoxicity to TECs by altering SIRT1 expression in vitro and in vivo, whereas the SIRT1-specific inhibitor EX527 exerted contrasting effects. In addition, we found that the protective effect of puerarin was related to the SIRT1/AKT/p38 signaling pathway. The findings suggest that puerarin regulates CaOx crystal-induced autophagy by activating the SIRT1-mediated signaling pathway, and they suggest a series of potential therapeutic targets and strategies for treating nephrolithiasis.

Available only for authorised users

Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y (2017) Epidemiology of stone disease across the world. World J Urol 35:1301–1320. https://doi.org/10.1007/s00345-017-2008-6CrossRefPubMed

Kusmartsev S, Dominguez-Gutierrez PR, Canales BK, Bird VG, Vieweg J, Khan SR (2016) Calcium oxalate stone fragment and crystal phagocytosis by human macrophages. J Urol 195:1143–1151. https://doi.org/10.1016/j.juro.2015.11.048CrossRefPubMed

Robijn S, Hoppe B, Vervaet BA, D’Haese PC, Verhulst A (2011) Hyperoxaluria: a gut-kidney axis? Kidney Int 80:1146–1158. https://doi.org/10.1038/ki.2011.287CrossRefPubMed

Evan AP (2010) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25:831–841. https://doi.org/10.1007/s00467-009-1116-yCrossRefPubMed

Sun XY, Ouyang JM, Yu K (2017) Shape-dependent cellular toxicity on renal epithelial cells and stone risk of calcium oxalate dihydrate crystals. Sci Rep 7:7250. https://doi.org/10.1038/s41598-017-07598-7CrossRefPubMedPubMedCentral

Mulay SR, Evan A, Anders HJ (2014) Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29:507–514. https://doi.org/10.1093/ndt/gft248CrossRefPubMed

Zhou T, Wang Z, Guo M, Zhang K, Geng L, Mao A, Yang Y, Yu F (2020) Puerarin induces mouse mesenteric vasodilation and ameliorates hypertension involving endothelial TRPV4 channels. Food Funct 11:10137–10148. https://doi.org/10.1039/d0fo02356fCrossRefPubMed

Wang C, Yao J, Ju L, Wen X, Shu L (2020) Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting β-cell neogenesis via GLP-1R signaling activation. Phytomedicine 70:153222. https://doi.org/10.1016/j.phymed.2020.153222CrossRefPubMed

Liu S, Cao XL, Liu GQ, Zhou T, Yang XL, Ma BX (2019) The in silico and in vivo evaluation of puerarin against Alzheimer’s disease. Food Funct 10:799–813. https://doi.org/10.1039/c8fo01696hCrossRefPubMed

10.

Zhou YX, Zhang H, Peng C (2014) Puerarin: a review of pharmacological effects. Phytother Res 28:961–975. https://doi.org/10.1002/ptr.5083CrossRefPubMed

11.

Han Y, Wang H, Wang Y, Dong P, Jia J, Yang S (2021) Puerarin protects cardiomyocytes from ischemia-reperfusion injury by upregulating LncRNA ANRIL and inhibiting autophagy. Cell Tissue Res 385:739–751. https://doi.org/10.1007/s00441-021-03463-2CrossRefPubMed

12.

Zhong Y, Lee K, He JC (2018) SIRT1 is a potential drug target for treatment of diabetic kidney disease. Front Endocrinol 9:624. https://doi.org/10.3389/fendo.2018.00624CrossRef

13.

He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43:67–93. https://doi.org/10.1146/annurev-genet-102808-114910CrossRefPubMedPubMedCentral

14.

Wu MY, Lu JH (2019) Autophagy and macrophage functions: inflammatory response and phagocytosis. Cells. https://doi.org/10.3390/cells9010070CrossRefPubMedPubMedCentral

15.

Choi AM, Ryter SW, Levine B (2013) Autophagy in human health and disease. N Engl J Med 368:651–662. https://doi.org/10.1056/NEJMra1205406CrossRefPubMed

16.

Duan X, Kong Z, Mai X, Lan Y, Liu Y, Yang Z, Zhao Z, Deng T, Zeng T, Cai C, Li S, Zhong W, Wu W, Zeng G (2018) Autophagy inhibition attenuates hyperoxaluria-induced renal tubular oxidative injury and calcium oxalate crystal depositions in the rat kidney. Redox Biol 16:414–425. https://doi.org/10.1016/j.redox.2018.03.019CrossRefPubMedPubMedCentral

17.

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113–118. https://doi.org/10.1038/nature03354CrossRefPubMed

18.

Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Méneur C, Permutt MA, Imai S (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2:105–117. https://doi.org/10.1016/j.cmet.2005.07.001CrossRefPubMed

19.

Salminen A, Kaarniranta K (2009) SIRT1: regulation of longevity via autophagy. Cell Signal 21:1356–1360. https://doi.org/10.1016/j.cellsig.2009.02.014CrossRefPubMed

20.

Hou J, Ding J, Li L, Peng Y, Gao X, Guo Z (2019) Association of sirtuin 1 gene polymorphisms with nephrolithiasis in Eastern Chinese population. Ren Fail 41:34–41. https://doi.org/10.1080/0886022x.2019.1568258CrossRefPubMedPubMedCentral

21.

Ye T, Yang X, Liu H, Lv P, Lu H, Jiang K, Peng E, Ye Z, Chen Z, Tang K (2021) Theaflavin protects against oxalate calcium-induced kidney oxidative stress injury via upregulation of SIRT1. Int J Biol Sci 17:1050–1060. https://doi.org/10.7150/ijbs.57160CrossRefPubMedPubMedCentral

22.

McMartin K (2009) Are calcium oxalate crystals involved in the mechanism of acute renal failure in ethylene glycol poisoning? Clin Toxicol 47:859–869. https://doi.org/10.3109/15563650903344793CrossRef

23.

Yamaguchi S, Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS (2005) Study of a rat model for calcium oxalate crystal formation without severe renal damage in selected conditions. Int J Urol 12:290–298. https://doi.org/10.1111/j.1442-2042.2005.01038.xCrossRefPubMed

24.

Tan C, Wang A, Liu C, Li Y, Shi Y, Zhou MS (2017) Puerarin improves vascular insulin resistance and cardiovascular remodeling in salt-sensitive hypertension. Am J Chin Med 45:1169–1184. https://doi.org/10.1142/s0192415x17500641CrossRefPubMed

25.

Han Y, Wang H, Wang Y, Dong P, Jia J, Yang S (2021) Puerarin protects cardiomyocytes from ischemia-reperfusion injury by upregulating LncRNA ANRIL and inhibiting autophagy. Cell Tissue Res. https://doi.org/10.1007/s00441-021-03463-2CrossRefPubMedPubMedCentral

26.

Du C, Zhang T, Xiao X, Shi Y, Duan H, Ren Y (2017) Protease-activated receptor-2 promotes kidney tubular epithelial inflammation by inhibiting autophagy via the PI3K/Akt/mTOR signalling pathway. Biochem J 474:2733–2747. https://doi.org/10.1042/bcj20170272CrossRefPubMed

27.

Nakamura S, Shigeyama S, Minami S, Shima T, Akayama S, Matsuda T, Esposito A, Napolitano G, Kuma A, Namba-Hamano T, Nakamura J, Yamamoto K, Sasai M, Tokumura A, Miyamoto M, Oe Y, Fujita T, Terawaki S, Takahashi A, Hamasaki M, Yamamoto M, Okada Y, Komatsu M, Nagai T, Takabatake Y, Xu H, Isaka Y, Ballabio A, Yoshimori T (2020) LC3 lipidation is essential for TFEB activation during the lysosomal damage response to kidney injury. Nat Cell Biol 22:1252–1263. https://doi.org/10.1038/s41556-020-00583-9CrossRefPubMed

28.

Zhang G, Wang Y, Tang G, Ma Y (2019) Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses. BMC Complement Altern Med 19:269. https://doi.org/10.1186/s12906-019-2691-5CrossRefPubMedPubMedCentral

29.

Xu X, Jiang R, Chen M, Dong M, Liu Q, Cheng H, Zhou K, Chen L, Li M, Jiang C (2019) Puerarin decreases collagen secretion in AngII-induced atrial fibroblasts through inhibiting autophagy via the JNK-Akt-mTOR signaling pathway. J Cardiovasc Pharmacol 73:373–382. https://doi.org/10.1097/fjc.0000000000000672CrossRefPubMed

30.

Liu Q, Wang C, Meng Q, Wu J, Sun H, Sun P, Ma X, Huo X, Liu K (2021) Puerarin sensitized K562/ADR cells by inhibiting NF-κB pathway and inducing autophagy. Phytother Res 35:1658–1668. https://doi.org/10.1002/ptr.6932CrossRefPubMed

31.

Yin L, Chen X, Li N, Jia W, Wang N, Hou B, Yang H, Zhang L, Qiang G, Yang X, Du G (2021) Puerarin ameliorates skeletal muscle wasting and fiber type transformation in STZ-induced type 1 diabetic rats. Biomed Pharmacother 133:110977. https://doi.org/10.1016/j.biopha.2020.110977CrossRefPubMed

32.

Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137–148. https://doi.org/10.1016/s0092-8674(01)00524-4CrossRefPubMed

33.

Packer M (2020) Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors. J Am Soc Nephrol 31:907–919. https://doi.org/10.1681/asn.2020010010CrossRefPubMedPubMedCentral

34.

Packer M (2020) Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation 141:2095–2105. https://doi.org/10.1161/circulationaha.119.045561CrossRefPubMed

35.

Gertz M, Fischer F, Nguyen GT, Lakshminarasimhan M, Schutkowski M, Weyand M, Steegborn C (2013) Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc Natl Acad Sci USA 110:E2772-2781. https://doi.org/10.1073/pnas.1303628110CrossRefPubMedPubMedCentral

36.

Sun Y, Dai S, Tao J, Li Y, He Z, Liu Q, Zhao J, Deng Y, Kang J, Zhang X, Yang S, Liu Y (2020) Taurine suppresses ROS-dependent autophagy via activating Akt/mTOR signaling pathway in calcium oxalate crystals-induced renal tubular epithelial cell injury. Aging 12:17353–17366. https://doi.org/10.18632/aging.103730CrossRefPubMedPubMedCentral

37.

Li H, Wang R (2017) Blocking SIRT1 inhibits cell proliferation and promotes aging through the PI3K/AKT pathway. Life Sci 190:84–90. https://doi.org/10.1016/j.lfs.2017.09.037CrossRefPubMed

38.

Zhang XS, Lu Y, Li W, Tao T, Peng L, Wang WH, Gao S, Liu C, Zhuang Z, Xia DY, Hang CH, Li W (2021) Astaxanthin ameliorates oxidative stress and neuronal apoptosis via SIRT1/NRF2/Prx2/ASK1/p38 after traumatic brain injury in mice. Br J Pharmacol 178:1114–1132. https://doi.org/10.1111/bph.15346CrossRefPubMed

Title: Puerarin prevents calcium oxalate crystal-induced renal epithelial cell autophagy by activating the SIRT1-mediated signaling pathway
Authors: Guan-Hua Jing
Ya-Dong Liu
Jian-Nan Liu
Yin-Shan Jin
Shi-Liang Yu
Rui-Hua An
Publication date: 01-08-2022
Publisher: Springer Berlin Heidelberg
Keyword: Urolithiasis
Published in: Urolithiasis / Issue 5/2022
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-022-01347-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Puerarin prevents calcium oxalate crystal-induced renal epithelial cell autophagy by activating the SIRT1-mediated signaling pathway

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

Predicting narrow ureters before ureteroscopic lithotripsy with a neural network: a retrospective bicenter study

Extremely slow, half-number shockwave lithotripsy for ureteral stones

What treatments reduce kidney stone risk in patients with bowel disease?

Complications and outcomes of tubeless versus nephrostomy tube in percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized clinical trials

The combination of mean and maximum Hounsfield Unit allows more accurate prediction of uric acid stones

Decision-making and improvements in health-related quality of life in patients with kidney stones: comparing surgery versus observation using a mixed methods analysis